Upgrade to SI Premium - Free Trial

Lilly’s Zepbound cuts risk of diabetes by 94% in obese patients, shares gain

August 20, 2024 7:59 AM
Eli Lilly (NYSE: LLY) said Tuesday its weight loss drug reduced the risk of developing type 2 diabetes by 94 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Hot List Momentum Movers

Next Articles